Holen Sie sich die Stockscreener-App
2.59
9.28%
0.22
Handel nachbörslich:
2.63
0.04
+1.54%
Schlusskurs vom Vortag:
$2.37
Offen:
$2.36
24-Stunden-Volumen:
4.95M
Relative Volume:
0.48
Marktkapitalisierung:
$190.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-3.2785
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
+4.44%
1M Leistung:
+262.85%
6M Leistung:
+515.64%
1J Leistung:
+318.42%
1-Tages-Spanne:
$2.26
$2.65
1-Wochen-Bereich:
$2.26
$2.65
52-Wochen-Spanne:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2403 SIDNEY STREET, PITTSBURGH
Vergleichen Sie CGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
2.59 | 214.38M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Does Cognition Therapeutics Inc. have pricing power2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - khodrobank.com
Cognition’s Alzheimer’s drug trial reaches 75% enrollment milestone - Investing.com
Trend analysis for Cognition Therapeutics Inc. this weekPortfolio Update Summary & AI Powered Trade Plan Recommendations - Newser
Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease Treatment - Quiver Quantitative
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target - GlobeNewswire
540-Patient Alzheimer's Trial: Cognition's Once-Daily Oral Drug Zervimesine Reaches Major Milestone - Stock Titan
Visualizing Cognition Therapeutics Inc. stock with heatmaps2025 AllTime Highs & Daily Profit Focused Screening - Newser
What’s next for Cognition Therapeutics Inc. stock price2025 Performance Recap & Growth-Oriented Investment Plans - Newser
What moving averages say about Cognition Therapeutics Inc.Weekly Trade Report & AI Enhanced Trade Execution Alerts - Newser
Top chart patterns to watch in Cognition Therapeutics Inc.2025 Biggest Moves & AI Forecast for Swing Trade Picks - Newser
MACD Cross Could Confirm Trend in Cognition Therapeutics Inc.Weekly Market Summary & AI Enhanced Trading Alerts - beatles.ru
Cognition Therapeutics shares fall 1.23% premarket after closing a $30 million registered direct offering. - AInvest
How to integrate Cognition Therapeutics Inc. into portfolio analysis toolsJuly 2025 Decliners & Advanced Technical Analysis Signals - Newser
Is Cognition Therapeutics Inc. still worth holding after the dipGold Moves & Free Safe Capital Growth Stock Tips - Newser
Cognition Therapeutics Inc. stock trend outlook and recovery pathTrade Analysis Summary & Technical Confirmation Trade Alerts - Newser
Real time scanner hits for Cognition Therapeutics Inc. explained2025 Valuation Update & Daily Chart Pattern Signal Reports - Newser
Published on: 2025-09-03 02:45:26 - Newser
Will Cognition Therapeutics Inc. stock go up soonJuly 2025 Momentum & Short-Term Swing Trade Alerts - Newser
How to build a custom watchlist for Cognition Therapeutics Inc.2025 Dividend Review & Scalable Portfolio Growth Ideas - Newser
What to expect from Cognition Therapeutics Inc. in the next 30 daysWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - Newser
Cognition Therapeutics Inc. stock retracement – recovery analysis2025 Technical Overview & Stock Timing and Entry Methods - Newser
Real time pattern detection on Cognition Therapeutics Inc. stockWeekly Profit Report & Consistent Return Strategy Ideas - Newser
Automated trading signals detected on Cognition Therapeutics Inc.Take Profit & Expert Curated Trade Setup Alerts - Newser
Cognition Therapeutics Inc. stock trend forecastJuly 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
Is Cognition Therapeutics Inc. trading at a discountJuly 2025 Trends & Smart Money Movement Alerts - khodrobank.com
Cognition Therapeutics Closes $30 Million Direct Offering - MarketScreener
Cognition Therapeutics closes $30 million registered direct offering - Investing.com
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) - GlobeNewswire
$30 Million Funding: Cognition Therapeutics Advances Breakthrough Neurodegenerative Drug to Phase 3 - Stock Titan
Chart overlay techniques for tracking Cognition Therapeutics Inc.Trade Volume Summary & Consistent Profit Alerts - Newser
Tick level data insight on Cognition Therapeutics Inc. volatilityBuy Signal & Weekly Breakout Watchlists - Newser
Cognition Therapeutics Inc. stock prediction for this weekJuly 2025 News Drivers & Technical Analysis for Trade Confirmation - Newser
Should you avoid Cognition Therapeutics Inc. stock right now2025 Trading Volume Trends & Real-Time Sentiment Analysis - خودرو بانک
How moving averages guide Cognition Therapeutics Inc. tradingJuly 2025 Spike Watch & Safe Entry Point Identification - Newser
Leading vs lagging indicators on Cognition Therapeutics Inc. performanceJuly 2025 Opening Moves & Reliable Trade Execution Plans - Newser
Intraday pattern recognizer results for Cognition Therapeutics Inc.Market Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Multi asset correlation models including Cognition Therapeutics Inc.July 2025 Earnings & Daily Stock Trend Reports - Newser
Ranking Cognition Therapeutics Inc. among high performing stocks via toolsPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Identifying reversal signals in Cognition Therapeutics Inc.Quarterly Portfolio Report & Verified Momentum Stock Watchlist - Newser
How sentiment analysis helps forecast Cognition Therapeutics Inc.2025 Investor Takeaways & Technical Buy Zone Confirmation - Newser
What technical models suggest about Cognition Therapeutics Inc.’s comeback2025 EndofYear Setup & Community Consensus Stock Picks - Newser
Is Cognition Therapeutics Inc. Forming a Bottom Pattern getLinesFromResByArray error: size == 0 - 더경남뉴스
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):